Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.9K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.9K
Preparation of 1° Amines: Gabriel Synthesis01:28

Preparation of 1° Amines: Gabriel Synthesis

4.7K
Direct alkylation is not a suitable method for synthesizing amines because it produces polyalkylated products. Gabriel synthesis is the most preferred method to exclusively make primary amines. The method uses phthalimide, which contains a protected form of nitrogen that participates in alkylation only once to predominantly give primary amines.
Strong bases like NaOH or KOH deprotonate the phthalimide to form the corresponding anion, which acts as a nucleophile. Further, the anion attacks an...
4.7K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

1.0K
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
1.0K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

10.7K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.7K
Preparation of 1° Amines: Azide Synthesis01:22

Preparation of 1° Amines: Azide Synthesis

4.7K
Direct alkylation of ammonia produces polyalkylated amines, along with a quaternary ammonium salt. To exclusively prepare primary amines, the azide synthesis method can be used.
Azide ions act as good nucleophiles and react with unhindered alkyl halides to form alkyl azides. Alkyl azides do not participate in further nucleophilic substitution reactions, thereby eliminating the chances of polyalkylated products. Alkyl azides are reduced by hydride-based reducing agents, like lithium aluminum...
4.7K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

3.9K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Does Metabolically Healthy Obesity Really Exist: Going Toward New Definitions.

The Journal of clinical endocrinology and metabolism·2026
Same author

Within- and Between-Day Reliability of Laboratory-Based Body Composition Assessment Methods.

The British journal of nutrition·2026
Same author

Comment on: Assessment of body composition following bariatric surgery using deuterium oxide derived method in adults with morbid obesity.

Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery·2026
Same author

Resuscitation Quality Improvement Program for CPR Training and Cardiac Arrest Survival in Hospitals.

JAMA cardiology·2026
Same author

Self-administration of oral voluntary assisted dying medication in Victoria, Australia: the first 6 years.

BMJ supportive & palliative care·2026
Same author

Temporal Trends in Direct-Acting Oral Anticoagulants Use Among Patients at Extremes of Body Weight: Insight From PINNACLE Registry.

Mayo Clinic proceedings. Innovations, quality & outcomes·2026
Same journal

Semisynthesis of Mycothiazole Analogs having Distinct Bioactivity.

ACS medicinal chemistry letters·2026
Same journal

Investigation on the Cytotoxicity of Hydroxycinnamic and Hydroxybenzoic Acid-Based Natural Antioxidant Conjugated Terpyridine Analogues toward Triple-Negative Breast Cancer.

ACS medicinal chemistry letters·2026
Same journal

Beyond Neddylation Inhibition: X‑ray Structures Reveal Carbonic Anhydrase Isoform Selectivity of Pevonedistat.

ACS medicinal chemistry letters·2026
Same journal

Structure-Guided Discovery of Selective Polo-Like Kinase 3 Inhibitors.

ACS medicinal chemistry letters·2026
Same journal

Controlling Neuroplasticity Across Scales: Constrained Serotonergic Agonists, Neuroplastogens, and Adaptive Neuromodulation.

ACS medicinal chemistry letters·2026
Same journal

Degradation and Detection: Integrating BCL6 Targeted Protein Degradation with Biomarker-Guided BET Inhibition in Cancer.

ACS medicinal chemistry letters·2026
See all related articles

Related Experiment Video

Updated: Feb 19, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K

Structure-Guided Development of NRAS G12D Inhibitors Based on a 5‑Azaindole Core.

Joshua B Cox1, Vinay Nair1, Pijus Mandal1

  • 1Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States.

ACS Medicinal Chemistry Letters
|February 18, 2026
PubMed
Summary
This summary is machine-generated.

Researchers developed IACS-56676, a targeted therapy for NRAS G12D mutations found in cancers like melanoma. This selective inhibitor offers a new tool for studying NRAS biology and cancer treatment.

Keywords:
G12D mutantKRAS inhibitorNRASSBDDprecision medicinestructure-based drug designtargeted therapy

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.4K
Preparation and In Vivo Use of an Activity-based Probe for N-acylethanolamine Acid Amidase
11:01

Preparation and In Vivo Use of an Activity-based Probe for N-acylethanolamine Acid Amidase

Published on: November 23, 2016

10.3K

Related Experiment Videos

Last Updated: Feb 19, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.4K
Preparation and In Vivo Use of an Activity-based Probe for N-acylethanolamine Acid Amidase
11:01

Preparation and In Vivo Use of an Activity-based Probe for N-acylethanolamine Acid Amidase

Published on: November 23, 2016

10.3K

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • NRAS G12D mutations drive melanoma and hematologic malignancies.
  • Targeted therapies for NRAS G12D are currently limited, representing an unmet clinical need.

Purpose of the Study:

  • To describe the structure-guided development of IACS-56676, a novel NRAS G12D inhibitor.
  • To establish IACS-56676 as a tool compound for NRAS biology research.
  • To gain insights into achieving selectivity between NRAS and KRAS proteins.

Main Methods:

  • Structure-guided drug design principles were employed.
  • Iterative optimization of lead compounds to enhance potency and selectivity.
  • Biochemical assays to assess inhibitor activity against NRAS and KRAS variants.

Main Results:

  • IACS-56676 was identified as a selective and potent inhibitor of NRAS G12D.
  • Key structural modifications, including p-loop stabilization and Leu 95 substitution, were crucial for activity.
  • The inhibitor demonstrated selectivity against wild-type KRAS and non-responder variants.

Conclusions:

  • IACS-56676 represents a significant advancement in targeting NRAS G12D mutations.
  • The compound serves as a valuable tool for further investigation of NRAS-driven oncogenesis.
  • The study provides a framework for developing selective RAS inhibitors.